Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D014777 | Virus Diseases NIH | 0.11 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study is designed rapidly assess safety and preliminary efficacy in hospitalized patients with COVID-19 respiratory distress to provide clinical guidance for possible wider use in treating patients in this pandemic environment. This data will be used for FDA IND filings and pursuit of a BLA.
Description: Frequency of all reported adverse events in study
Measure: Frequency of all adverse events Time: Through study completion, an average of three monthsDescription: Frequency of SAEs in the 6 hours post-infusion for each infusion
Measure: Frequency of infusion related serious adverse events Time: 6 hours post infusionDescription: Frequency of all serious adverse events in study
Measure: Frequency of serious adverse events Time: Through study completion, an average of three monthsDescription: All-cause mortality through Day 28
Measure: Mortality Time: Study days 0-28Description: Ventilator free days through Study day 28
Measure: Ventilator Free Days Time: Study days 0-28Description: Total days not in ICU from Study day 0 through Study day 28
Measure: ICU Free Days Time: Days 0 through 28Description: Total Days in Hospital from Day 0 through discharge for survivors
Measure: Total Hospital Days Time: Days 0 through discharge, an average of 28 daysDescription: Total Days in ICU from Day 0 through discharge for survivors
Measure: Total ICU Days Time: Days 0 through discharge, an average of 28 daysDescription: Improvement in oxygenation comparing Study day 0, to days 2, 4, 6
Measure: Improvement in Oxygenation Time: Study days 0, 2, 4, 6Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports